Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial.

MLA

Mair, Maximilian J., et al. “Prophylactic Treatment with Oral Azithromycin in Cancer Patients during the COVID-19 Pandemic (OnCoVID): A Randomized, Single-Blinded, Placebo-Controlled Phase 2 Trial.” Infectious Agents & Cancer, vol. 18, no. 1, Feb. 2023, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s13027-023-00487-x.

APA

Mair, M. J., Maj-Hes, A., Nussbaumer-Pröll, A., Puhr, R., Christenheit, A., Troch, M., Puhr, H. C., Starzer, A. M., Steindl, A., Eberl, S., Haslacher, H., Perkmann, T., Minichsdorfer, C., Prager, G. W., Lamm, W. W., Berghoff, A. S., Kiesewetter, B., Zeitlinger, M., Preusser, M., & Raderer, M. (2023). Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial. Infectious Agents & Cancer, 18(1), 1–10. https://doi.org/10.1186/s13027-023-00487-x

Chicago

Mair, Maximilian J., Agnieszka Maj-Hes, Alina Nussbaumer-Pröll, Rainer Puhr, Agnieszka Christenheit, Marlene Troch, Hannah C. Puhr, et al. 2023. “Prophylactic Treatment with Oral Azithromycin in Cancer Patients during the COVID-19 Pandemic (OnCoVID): A Randomized, Single-Blinded, Placebo-Controlled Phase 2 Trial.” Infectious Agents & Cancer 18 (1): 1–10. doi:10.1186/s13027-023-00487-x.